Tushar Pandey: From ITP to TTP in Clinical Practice
Tushar Pandey, Director and Head of Raghav Institute of Hematology, Hemato-Oncology and BMT at Raghav Healthcare, Editorial Board Member at Journal of Cancer Chemotherapy, Program Director of Hemato – Oncology at International Association For Integrated Oncology, shared a post on LinkedIn:
“Always a pleasure to speak about thrombocytopenia, especially ITP and TTP.
These conditions are commonly seen but still challenge clinicians due to their changing presentations, evolving evidence, and the need for timely and accurate decision-making.
From immune thrombocytopenia (ITP), where individualized treatment and long-term disease control are essential, to thrombotic thrombocytopenic purpura (TTP), a true hematologic emergency requiring rapid recognition and intervention, they reflect the complexity of real – world hematology practice.
Each opportunity like this helps bridge guidelines with real – life practice, ensuring patients receive evidence – based, practical, and life – saving care.
Grateful to contribute to the advancement of hematology, hemato-oncology, and BMT through knowledge sharing and clinical excellence.”
Stay updated with Hemostasis Today.
-
Sep 11, 2026, 13:35How Non-Factor Therapies Are Changing Hemophilia Care – Seminars in Thrombosis and Hemostasis
-
Sep 11, 2026, 13:21Emmanuel J Favaloro: Rethinking Quality Control in VWD Testing
-
Sep 11, 2026, 13:10Tessa Youngner: New Free E-Course Introduces Comprehensive SCD Care
-
Sep 11, 2026, 12:55Identifying Key Research Priorities for VTE and Stroke – International Journal of Stroke
-
Sep 11, 2026, 12:43Helping Hematology Employers Reach Qualified Job Seekers – ASH
-
Sep 11, 2026, 12:22The First New Treatment for Essential Thrombocythemia in Nearly 30 Years
-
Sep 11, 2026, 12:20When Thrombosis Affects the Kidneys – World Thrombosis Day
-
Sep 11, 2026, 11:24Haroun Gajraj: Polidocanol or STS – Choosing the Right Sclerosant
-
Sep 11, 2026, 10:53A Patient-Centred Approach to Haemophilia B Care – EAHAD